Related Experiment Video
Updated: Aug 24, 2026
Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats
Published on: April 15, 2016
[Human antisense-vascular endothelial growth factor gene therapy for laryngeal tumor by cationic liposome-mediated
Zhi-hong Deng1, Min Jin, Wei-guo Huang
1Department of Otorhinolaryngology, Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China. dengzh@fmmu.edu.cn
Objective:
To observe the effect of cationic liposome mediated antisense-vascular endothelial growth factor (VEGF) gene transfection on the growth of laryngeal cancer Hep-2 cells in the nude mice.
Methods:
The VEGF-cDNA gene was cloned by reverse transcriptase polymerase chain reaction (RT-PCR) from human laryngeal cancer, and its eukaryotic expression vector pcDNA3-VEGF (-) with antisense-VEGF gene was constructed and identified by PCR and double-enzyme digestion. The pcDNA3-VEGF (-) was transfected into laryngeal cancer Hep-2 cell line by using cationic liposome (LP 2000). Then, the transfected Hep-2 cells were injected into nude mice and the size of tumor from different groups was observed while establishing laryngeal cancer xenografts in nude mice, and then treating the tumor-bearing mice with liposome-plasmid complex, observing the size of tumor from different groups. The expression of VEGF mRNA in different groups was observed by RT-PCR. The transfected cell ultranstructure was observed by transmission electron microscopy.
Results:
The human VEGF-cDNA was successfully cloned and its eukaryotic expression vector with antisense-VEGF pcDNA3-VEGF (-) was constructed. The antisense-VEGF gene was transfected into Hep-2 cell line by using cationic liposome (LP2000). The size of tumor transfected with pcDNA3-VEGF (-) was significantly smaller than that of control groups. While the size of tumor treated with liposome-pcDNA3-VEGF (-) complex was significantly smaller than that of control groups. Many apoptic tumor cells were observed by transmission electron microscopy and the structure of microvessel was also changed. The expression of VEGF mRNA was evidently weaker than that of the control groups.
Conclusion:
The growth of Hep-2 cells could be inhibited significantly by antisense-VEGF gene transfection.
Insights
Antisense-vascular endothelial growth factor (VEGF) gene transfection significantly inhibited laryngeal cancer Hep-2 cell growth in nude mice. This gene therapy approach offers a promising strategy for laryngeal cancer treatment.
Area of Science:
- Molecular Biology
- Gene Therapy
- Oncology
Context:
- Laryngeal cancer poses a significant health challenge, necessitating novel therapeutic strategies.
- Vascular endothelial growth factor (VEGF) plays a crucial role in tumor angiogenesis and progression.
- Gene therapy offers a targeted approach to inhibit tumor growth by downregulating key oncogenic factors.
Purpose:
- To investigate the efficacy of cationic liposome-mediated antisense-vascular endothelial growth factor (VEGF) gene transfection in inhibiting laryngeal cancer Hep-2 cell growth.
- To evaluate the impact of antisense-VEGF gene delivery on tumor size and VEGF mRNA expression in a xenograft model.
Summary:
- Human VEGF-cDNA was cloned, and an antisense-VEGF eukaryotic expression vector (pcDNA3-VEGF (-)) was constructed.
- Antisense-VEGF gene was successfully transfected into Hep-2 cells using cationic liposomes (LP2000).
- Transfected tumors and liposome-treated tumors showed significantly reduced size, decreased VEGF mRNA expression, and increased apoptosis compared to controls.
Impact:
- Cationic liposome-mediated antisense-VEGF gene transfection demonstrates significant inhibition of laryngeal cancer Hep-2 cell growth.
- This approach alters tumor cell ultrastructure, induces apoptosis, and modifies microvessel structure.
- The findings suggest a potential therapeutic application of antisense-VEGF gene therapy for laryngeal cancer.
